Vale Biolabs secures €164K Venture Kick funding to drive AI-powered brain disease research

Vale Biolabs has secured €164,000 from Venture Kick to accelerate its research on brain diseases using a platform that integrates lab-grown human brain tissue, automation, and predictive artificial intelligence.

The funding aims to support the biotech startup’s efforts to evaluate new therapies for neurological conditions, a field where breakthroughs could reshape drug development across Europe and beyond. The company, co-founded by Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano, and Theodoulos Rodosthenous, plans to use the investment to refine its innovative approach, which blends biological models with AI-powered analytics.

This combination of cutting-edge laboratory techniques and automation allows for more accurate simulation and prediction of disease progression and treatment outcomes. The approach could shorten the path from research to clinical application, a persistent challenge in neuroscience.

Vale Biolabs’ platform holds the potential to attract further investment and foster collaborations with pharmaceutical companies seeking to accelerate their own drug pipelines. The startup’s reliance on continuous funding highlights the broader risk environment faced by early-stage biotech ventures, particularly those working at the intersection of AI and life sciences.

Venture Kick’s investment signals growing recognition of the role AI can play in advancing medical research and bolstering Europe’s biotech ecosystem. For Latin American stakeholders, the evolution of such technologies may present future opportunities for cross-border partnerships and technology transfer.